

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. ___)*

Milestone Pharmaceuticals Inc.
(Name of Issuer)

Common Shares
(Title of Class of Securities)

59935V107
(CUSIP Number)

May 13, 2019
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Fonds de solidarité des travailleurs du Québec (F.T.Q.) (hereinafter referred to as "Fonds")	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP N/A	(a) <input type="radio"/> (b) <input type="radio"/>
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Montreal (Quebec) Canada	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 2,720,310 Common Shares
	6	SHARED VOTING POWER N/A
	7	SOLE DISPOSITIVE POWER 2,720,310 Common Shares
	8	SHARED DISPOSITIVE POWER N/A
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,720,310 Common Shares	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	<input type="radio"/>
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11.5% ¹	
12	TYPE OF REPORTING PERSON IV	

¹ The percentage ownership interest is determined based on 23,647,589 Common Shares outstanding, as reported by the Issuer in its prospectus dated May 8, 2019.

Item 1. (a) Name of Issuer:

Milestone Pharmaceuticals Inc.

(b) Address of Issuer's Principal Executive Offices:

1111 Dr. Frederik-Philips Blvd.
Montreal, Quebec CANADA
H4M 2X6

Item 2. (a) Names of Person Filing:

Fonds de solidarité des travailleurs du Québec (F.T.Q.)

(b) Address of Principal Business Office:

545, Cremazie Blvd. East, # 200
Montreal, Quebec CANADA
H2M 2W4

(c) Citizenship:

See row 4 of cover page.

(d) Title of Class of Securities:

Common Shares

(e) CUSIP Number:

59935V107

Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

N/A

Item 4. Ownership.**(a) Amount beneficially owned:**

See row 9 of cover page.

(b) Percent of class:

See row 11 of cover page.

(c) **Number of shares as to which the person has:**

(i) Sole power to vote or to direct the vote:

See row 5 of cover page.

(ii) Shared power to vote or to direct the vote:

See row 6 of cover page.

(iii) Sole power to dispose or to direct the disposition of:

See row 7 of cover page.

(iv) Shared power to dispose or to direct the disposition of:

See row 8 of cover page.

Item 5. Ownership of Five Percent or Less of a Class:

No

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

N/A

Item 8. Identification and Classification of Members of the Group:

N/A

Item 9. Notification of Dissolution of Group:

N/A

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated as of May 15, 2019

Fonds de solidarité des travailleurs du Québec (F.T.Q.)

By: /s/ Liette Leduc

Liette Leduc

Senior Director – Legal Affairs
